Publications by authors named "K J Labori"
Article Synopsis
- A study explored the link between a bacterial metabolite, indole 3-acetate (3-IAA), and chemotherapy response in non-metastatic pancreatic ductal adenocarcinoma (PDAC) patients, building on previous findings in metastatic cases.
- Researchers measured 3-IAA levels in blood from 124 patients with locally advanced or borderline resectable PDAC before they started chemotherapy, primarily FOLFIRINOX.
- The results showed no significant association between pre-treatment 3-IAA levels and overall survival, suggesting that the positive effects seen in metastatic cases may not apply to non-metastatic patients, highlighting the need for further research.
Background: Tailoring surgical treatment is mandatory to optimize outcomes in chronic pancreatitis. Total pancreatectomy (TP) offers pain relief in a subset of patients. TP with islet autotransplantation (IAT) has the potential to reduce the burden of postsurgical diabetes.
View Article and Find Full Text PDFGlobal metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer.
Mol Oncol
November 2024
Neoadjuvant chemotherapy (NAT) is increasingly used for the treatment of non-metastatic pancreatic ductal adenocarcinoma (PDAC) and is established as a standard of care for borderline resectable and locally advanced PDAC. However, full exploitation of its clinical benefits is limited by the lack of biomarkers that assess treatment response. To address this unmet need, global metabolomic profiling was performed on tumor tissue and paired serum samples from patients with treatment-naïve (TN; n = 18) and neoadjuvant leucovorin calcium (folinic acid), fluorouracil, irinotecan hydrochloride and oxaliplatin (FOLFIRINOX)-treated (NAT; n = 17) PDAC using liquid chromatography mass spectrometry.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to determine the need for routine surveillance after pancreatic cancer surgery and to analyze surveillance practices in Nordic countries.
- A review of global clinical guidelines and a survey of 20 pancreatic units in Norway, Sweden, Denmark, and Finland revealed inconsistent recommendations and practices regarding postoperative follow-up.
- Despite most units conducting routine surveillance, evidence supporting long-term monitoring (up to 5 years) is limited and varies significantly between institutions.
Background: International guidelines currently recommend the use of molecular testing in patients with advanced pancreatic cancer. The rate of actionable molecular alterations is low. The utility of molecular testing in patients with borderline resectable (BRPC) or locally advanced (LAPC) pancreatic cancer in real world clinical practice is unclear.
View Article and Find Full Text PDF